Related Experiment Video
Updated: Jul 2, 2026
03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
Debunking Constipation Myths: What Community Pharmacists Need to Know
1Community Pharmacist in Madrid, Spain. Member of the SEFAC Nutrition and Digestive Health Working Group España.
Farmaceuticos Comunitarios
|July 1, 2026
Summary
Common constipation myths, like needing daily bowel movements or laxative addiction, are scientifically unfounded. Pharmacists can combat these misconceptions with evidence-based patient education to improve care.
Area of Science:
- Gastroenterology
- Pharmacology
- Public Health
Background:
- Constipation is a widespread gastrointestinal disorder impacting quality of life and healthcare.
- Management is challenged by persistent myths and beliefs hindering effective treatment.
- Addressing these misconceptions is crucial for appropriate healthcare intervention.
Purpose of the Study:
- To identify, analyze, and clarify prevalent myths surrounding constipation.
- To provide community pharmacists with evidence-based tools for patient education.
- To enhance clinical practice and improve patient outcomes in constipation management.
Main Methods:
- A narrative review of scientific literature from 2015-2025.
- Searches conducted in biomedical databases (PubMed, ScienceDirect, Cochrane) and institutional sources.
- Inclusion of articles, guidelines, and consensus documents on constipation myths.
Main Results:
- Identified common misconceptions: daily bowel movement necessity, fluid/olive oil efficacy, laxative harm, gender specificity, and colorectal cancer links.
- Explored misunderstandings regarding fiber, probiotics, and specific food roles.
- Revealed a significant gap between popular beliefs and scientific evidence.
Conclusions:
- Community pharmacists are vital in dispelling constipation myths.
- Evidence-based, personalized patient education is essential.
- Addressing misconceptions improves constipation management and patient care.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...